Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q1 2022, posting revenues of $8.06 million, a 124% increase year-over-year and a 34% rise sequentially. Gross margins expanded to 49.4% (GAAP) and 61% (non-GAAP). The company added 14 new B2B accounts, including two health plans, and secured a $30 million agreement with Sanofi to enhance its market outreach. Despite an operating loss of $15.9 million, DarioHealth improved its financial position by reducing operating costs and marketing expenses, indicating a positive trend in its B2B transformation.

DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q1 2022 on May 12, 2022, hosting a conference call and webcast at 8:30 am ET. Key executives, including CEO Erez Raphael, will lead the discussion. Interested participants can join via dial-in or the provided webcast link. A replay will be available after the call until June 12, 2022. DarioHealth specializes in digital therapeutics for chronic conditions, offering an innovative platform that integrates multiple health solutions.

DarioHealth Corp. (Nasdaq: DRIO) showcased a study at the ATTD Conference revealing effective diabetes and weight management outcomes via its integrated digital therapeutics platform. Analyzing data from 715 individuals, nearly two-thirds reduced their BMI by an average of 2.8 units and achieved a 7.4% weight loss. A subgroup with high-risk blood glucose levels experienced a 4.9% weight loss and a 16.1% reduction in blood glucose over 12 months. This study underscores Dario’s holistic approach, which could significantly impact chronic condition management.

DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Colorado Access, the largest public sector health plan in Colorado, to enhance digital chronic condition management for underserved populations. Starting in Q2 2022, Dario will provide integrated solutions for members managing diabetes, hypertension, weight, and behavioral health needs. This collaboration aims to deliver personalized care using Dario's comprehensive digital therapeutics platform, combining tools, devices, and coaching. The partnership reflects a growing recognition of the importance of digital health in improving member outcomes.

DarioHealth Corp. (Nasdaq: DRIO) reported a substantial revenue increase of 171%, reaching $20.5 million for 2021, driven by its B2B growth and acquisitions. The fourth quarter saw a revenue rise to $6.03 million, a 190% year-on-year increase. However, gross profit as a percentage declined to 9.1%. Operating expenses surged to $22.2 million, leading to an operating loss of $21.7 million. A notable collaboration with Sanofi aims to enhance market presence. Cash reserves stood at $35.8 million, supplemented by a $40 million raise in March 2022 to support ongoing strategic initiatives.

DarioHealth Corp. (Nasdaq: DRIO) will release its financial results for the fourth quarter and full year ended December 31, 2021, on March 21, 2022, post-market close. A conference call will be held on March 22, 2022, at 8:30 am EDT, featuring CEO Erez Raphael and other executives. Participants should join 10 minutes early, with a replay available until April 22, 2022. DarioHealth focuses on digital therapeutics to manage chronic conditions through AI-powered tools and personalized experiences.

DarioHealth Corp. (Nasdaq: DRIO) will participate in the Cowen 42nd Annual Healthcare Conference virtually from March 7-9, 2022. CEO Erez Raphael and President Rick Anderson will hold a fireside chat on March 8 from 11:10-11:40 AM ET. A live webcast will be available here and on their Investor Relations website, with a replay accessible for 90 days. DarioHealth specializes in digital therapeutics, providing solutions for chronic conditions and promoting health improvements through AI-driven, personalized platforms.